US Patent Issued to Memorial Sloan Kettering Cancer Center on Aug. 25 for "DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy" (New York Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,714,758, issued on Aug. 25, was assigned to Memorial Sloan Kettering Cancer Center (New York).

"DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy" was invented by Steven Larson (New York), Darren Veach (New York), Sarah Taldone (New York), Ouathek Ouerfelli (New York), Guangbin Yang (New York), Nai-Kong Cheung (New York), Brian Santich (New York) and Hong Xu (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds tha...